- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02234180
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
Randomized Phase II Double Blind Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To compare the disease-free survival (DFS) for patients with resected esophageal and gastroesophageal (GE) junction adenocarcinoma treated with regorafenib vs. placebo in the adjuvant setting.
SECONDARY OBJECTIVES:
I. To compare the safety profile of adjuvant regorafenib vs. placebo in patients with locally advanced resectable esophageal and GE junction adenocarcinoma.
II. To compare the overall survival (OS) for patients with resected esophageal and GE junction adenocarcinoma treated with regorafenib vs. placebo in the adjuvant setting.
III. To compare the DFS in those patients that receive at least 1 cycle of therapy.
IV. To collect tumor samples for future genomic analysis to explore the biology of locally advanced esophageal and GE junction adenocarcinoma.
V. DFS will be compared between the arms from the time of surgery as well.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Within 6-12 weeks after surgery, patients receive regorafenib orally (PO) once daily (QD) on days 1-21.
ARM II: Within 6-12 weeks after surgery, patients receive placebo PO QD on days 1-21.
In both arms, courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years, and every 6 months for up to 5 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Illinois
-
Urbana, Illinois, United States, 61801
- Carle Cancer Center
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Cancer Center of Kansas - Wichita
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Medical Center Jefferson
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Nebraska
-
Omaha, Nebraska, United States, 68106
- Missouri Valley Cancer Consortium
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth Hitchcock Medical Center
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Comprehensive Cancer Center of Wake Forest University
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
Toledo, Ohio, United States, 43623
- Toledo Clinic Cancer Centers-Toledo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological confirmation of node positive (any T stage N1-3) proximal esophageal, distal esophagus or gastroesophageal (GE) junction adenocarcinoma (Siewert I, II, or III) after completing preoperative chemoradiation and surgery; supporting pathology report sufficient for registration; available tumor tissue from endoscopic biopsies prior to preoperative chemotherapy (chemo)/radiation therapy (RT), and tumor from surgical specimens will be submitted to Academic and Community Cancer Research United (ACCRU), but not be required prior registration; Note: if tissue is depleted, patient will still be eligible after discussion with the physician
- Imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) =< 28 days of study registration negative for disease recurrence
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- Absolute neutrophil count (ANC) >= 1500/mm^3
- Platelet count >= 100,000/mm^3
- Total bilirubin =< 1.5 x the upper limits of normal (ULN)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
- Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
- Lipase =< 1.5 x the ULN
- Serum creatinine =< 1.5 x the ULN
- International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN; Note-subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that their medication dose and INR/PTT are stable; close monitoring (day 1 of each cycle) is mandatory; if either of these values is above the therapeutic range, the doses should be modified and the assessments should be repeated weekly until they are stable
- Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- Provide informed written consent
- Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
- Able to swallow and retain oral medications and begin therapy within 6 to 12 weeks post-surgery
- Provide blood samples for the mandatory correlative research purposes
Exclusion Criteria:
- Presence of metastatic or recurrent disease
- R1 or R2 resection
- Patients who have not recovered from serious adverse events (as determined by treating doctor of medicine [MD]) related to surgery
- Uncontrolled hypertension (systolic pressure > 140 mm Hg or diastolic pressure > 90 mm Hg on repeated measurement) despite optimal medical management per physician discretion
Active or clinically significant cardiac disease including:
- Congestive heart failure - New York Heart Association (NYHA) > class II
- Active coronary artery disease
- Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin
- Unstable angina (anginal symptoms at rest), new-onset angina < 3 months before randomization, or myocardial infarction within 6 months before randomization
- Evidence or history of bleeding diathesis or coagulopathy
- Any hemorrhage or bleeding event >= National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4 grade 3 =< 4 weeks prior to registration
- Prior cancers < 3 years, with the exception of in-situ cervical cancer, low grade prostate cancer and basal or squamous cell skin cancers
- Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism =< 6 months prior to registration
- Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4); use of strong or moderate inhibitors are prohibited =< 7 days to registration
- Receiving any medications or substances that are inducers of CYP3A4; use of inducers are prohibited =< 7 days prior to registration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (regorafenib)
Within 6-12 weeks after surgery, patients receive regorafenib PO QD on days 1-21.
Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
|
Placebo Comparator: Arm II (placebo)
Within 6-12 weeks after surgery, patients receive placebo PO QD on days 1-21.
Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Free Survival (DFS)
Time Frame: Time from randomization to the first of either disease recurrence or death from any cause, assessed up to 1 year and 10 months
|
Disease free survival (DFS) is defined as the time from randomization to the first of either disease recurrence or death from any cause.
The distribution of DFS will be estimated using the Kaplan Meier method.
|
Time from randomization to the first of either disease recurrence or death from any cause, assessed up to 1 year and 10 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4)
Time Frame: Up to 1 year and 10 months
|
The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns within patient groups.
In addition, we will review all adverse event data that is graded as 3, 4, or 5 and classified as either "unrelated" or "unlikely to be related" to study treatment in the event of an actual relationship developing.
The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below.
|
Up to 1 year and 10 months
|
Overall Survival (OS)
Time Frame: Time from randomization to death due to any cause, assessed up to 1 year and 10 months
|
Overall survival (OS) is defined as the time from randomization to death due to any cause.
|
Time from randomization to death due to any cause, assessed up to 1 year and 10 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Yelena Janjigian, Academic and Community Cancer Research United
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RU021212I (Other Identifier: Academic and Community Cancer Research United)
- P30CA015083 (U.S. NIH Grant/Contract)
- NCI-2015-01699 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- NCI-2014-01962
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma of the Gastroesophageal Junction
-
Accelerated Community Oncology Research NetworkAmgenTerminatedGastroesophageal Adenocarcinoma | Adenocarcinomas of the Gastroesophageal Junction | Adenocarcinoma of the Distal Esophagus | Adenocarcinoma of the Proximal StomachUnited States
-
UNICANCERBayerTerminatedAdenocarcinoma of the Gastroesophageal Junction | Adenocarcinoma of the StomachFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingClinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage III... and other conditionsUnited States
-
Medical University of LublinUnknownAdenocarcinoma of the Gastroesophageal JunctionPoland
-
University of Colorado, DenverNational Cancer Institute (NCI)RecruitingAdenocarcinoma of the Gastroesophageal Junction | Adenocarcinoma EsophagusUnited States
-
P. C. Thuss-PatienceRecruitingGastroesophageal Junction Adenocarcinoma | Adenocarcinoma of the StomachGermany
-
Institut für Klinische Krebsforschung IKF GmbH...CompletedGastric Adenocarcinoma | Metastatic Adenocarcinoma of the Gastroesophageal JunctionGermany
-
Milton S. Hershey Medical CenterCompletedPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Adenocarcinoma of the Gastroesophageal JunctionUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingEsophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteAventis PharmaceuticalsTerminatedEsophageal Adenocarcinomas | Adenocarcinomas of the Gastroesophageal JunctionUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States